Skip to main content
. 2017 Feb 1;8(14):23073–23086. doi: 10.18632/oncotarget.14981

Figure 3. Primary human bone marrow stroma cell supernatant collected from a leukemia patient in remission protects primary leukemia cells from Ara-C induced cytotoxicity.

Figure 3

THP1 cells (A) and purified human primary leukemia cells from a patient with AML (Patient C) (B) were cultured with or without primary human BMSC SN collected from the patient before and after chemotherapy treatment and confirmed remission, for 2 hours before treatment with Ara-C (1.6, 6 and 25 μg/ml) for 24 hours (THP-1 cells) or Ara-C (625, 2500 and 10000 μg/ml) for 72 hours (primary leukemia cells). Leukemia cell viability was assessed by the MTT assay. Each bar represents the mean ± SD of 3 independent experiments. *p < 0.05; **p < 0.01 ***p < 0.001 (leukemia cells in normal medium (RPMI) versus leukemia cells in patient's BM stroma).